ArticlePloS one2026
Epidemiological and genomic analysis of the dengue virus isolate from Jeddah, Saudi Arabia: Implications for future therapeutic development.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue fever is one of the major mosquito-borne diseases worldwide, and studies have shown that more than half of the world population could be at risk of dengue in the future. To date, there are no universally effective vaccines or specific antiviral treatments for dengue virus (DENV). Dengue fever has reported in the Western region of Saudi Arabia since 1994. A comprehensive understanding of the molecular epidemiology of the DENV in Saudi Arabia, with implications for therapeutic development, is still absent.
aimThe present study aimed to integrate analysis of the circulating DENV genome and mutations of the most prevalent dengue serotype in the therapeutic context.
methodsRetrospective data were used to conduct analysis of dengue infections in Jeddah city in Saudi Arabia from January to October 2024. All Saudis, non-Saudis, and Hajj and Umrah visitors with a confirmed diagnosis of dengue fever were included in the study. The demographic factors and DENV serotypes were explored. The genome of the most prevalent DENV serotype was sequenced using Oxford Nanopore Technology. Closely related strains were searched using the BLAST NCBI tool, and the NGPhylogeny server was used to analyze the phylogenetic relationship. In order to provide a biologically appropriate template for drug-design initiative, the dengue structural protein (prM) of an isolated strain was optimized through receptor modeling and mutation analysis using ICM tool.
resultsAnalysis of the circulating DENV serotypes showed that higher incidence rates occurred in young adults, males, and from the Middle Eastern region of origin. The majority (95.3%) of confirmed cases were caused by the serotype DENV-2. A high nucleotide sequence identity was noted for strains originating from Pakistan (99.68%). Five ligands containing nitrogen-rich chemical scaffolds (piperidine, azoles, and sulfonamides) with a variety of substituents were identified by the study as possible binding hits to both wild-type and mutant prM receptor structures. Although of limited sample size and preliminary docking results, the epidemiological and molecular data generated in the study provide useful information for epidemic preparedness and possible therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.